Research and Markets: Gain an Insight into the Financial Performance & Future Outlook for Amgen.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47418) has announced the addition of the Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd report: Amgen Prospects to 2010 to their offering. Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Amgen operates in one business segment - human therapeutics, and markets products in the areas of haematology, immunology, inflammation and oncology. This report provides a full review of the company's activities together with sales forecasts for key products to 2010. Amgen was incorporated in 1980 and is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics. Amgen opertates in one business segment - human therapeutics, and markets products in the areas of haematology, immunology, inflammation and oncology. Research and development efforts are focussed on novel theraputics for the treatment of haematology, inflammation, oncology, metabolic disorders and neuroscience. Current Growth Drivers Since Amgen markets a small number of products, they are all very significant to the company. Three products in particular have shown strong sales growth in recent years: Aranesp (darbepoetin alpha), a novel erythropoiesis erythropoiesis /eryth·ro·poi·e·sis/ (-poi-e´sis) the formation of erythrocytes.erythropoiet´ic e·ryth·ro·poi·e·sis n. The formation or production of red blood cells. stimulating protein, is a recombinant protein which stimulates the production of red blood cells Red blood cells Cells that carry hemoglobin (the molecule that transports oxygen) and help remove wastes from tissues throughout the body. Mentioned in: Bone Marrow Transplantation red blood cells . In 2005, Aranesp usage in US hospital dialysis clinics increased, reflecting a conversion from Epogen in the treatment of various causes of anaemia. Neulasta (pegfilgrastim) is a sustained-duration formulation of Neupogen (filgrastim) formed by the addition of polyethylene glycol to granulocyte granulocyte /gran·u·lo·cyte/ (gran´u-lo-sit?) granular leukocyte.granulocyt´ic band-form granulocyte band cell. gran·u·lo·cyte n. colony stimulating factor colony stimulating factor n. A hormone produced in the cells lining the blood vessels that stimulates the bone marrow to synthesize white blood cells. and developed in collaboration with Roche. Neulasta has demonstrated continued market gains since its launch in 2002. This rise in sales can be attributed to an increased awareness of febrile neutropenia. Enbrel (etanercept) is a soluble tumour necrosis factor Noun 1. tumour necrosis factor - a proinflammatory cytokine that is produced by white blood cells (monocytes and macrophages); has an antineoplastic effect but causes inflammation (as in rheumatoid arthritis) TNF, tumor necrosis factor which has potential in several inflammatory diseases mediated by excess TNF TNF abbr. tumor necrosis factor TNF, n an abbreviation for tumor necrosis f . Enbrel sales growth has benefited from its competitive profile and significant increases in the usage of biologics in both rheumatology and dermatology settings. Topics Covered Principal Operating Results Breaking News Latest Results Executive Summary Product Portfolio / Research & Development Appendix 1 - Financial Performance Appendix 2 - Key Corporate Events Appendix 3 - Key Agreements Appendix 4 - Infrastructure Appendix 5 - Key Pharmaceutical Subsidiaries / Joint Ventures Appendix 6 - Product Index Index of Tables Companies Mentioned * Abgenix Inc * Biovitrum AB * Boehringer Ingelheim Pharma KG * Cambridge Antibody Technology Ltd (CAT) * Celltech Group plc * Eli Lilly * Genmab A/S * GlaxoSmithKline * Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. Inc (HGS HGS Human Genome Sciences, Inc. (Rockville, Maryland) HGS Heads Up Guidance System HGS Halifax Grammar School (Halifax, Canada) HGS Hangars HGS Heckmondwike Grammar School (UK) ) * Infinity Pharmaceuticals Incorporated 89 * Amgen * InterMune Inc * Johnson & Johnson * Kirin Brewery Co Ltd/ Kirin-Amgen * Medarex Inc * NeoGenesis ne·o·gen·e·sis n. Regeneration of tissue. ne  o·ge·net ic adj. Pharmaceuticals Inc * NPS NPS National Park Service NPS Naval Postgraduate School NPS Net Promoter Score (customer management) NPS Non-Point Source pollution NPS Native Plant Society NPS Norfolk Public Schools (Virginia) Pharmaceuticals Inc * Regeneron Pharmaceuticals Inc * Roche * SkyePharma Plc * Wyeth * ZymoGenetics Inc For more information visit http://www.researchandmarkets.com/reports/c47418. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion